Article
HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis.
Haematologica - 1 Nov 2017
Huang Rui, Hayashi Yoshihiro, Yan Xiaomei, Bu Jiachen, Wang Jieyu, Zhang Yue, Zhou Yile, Tang Yuting, Wu Lingyun, Xu Zefeng, Liu Xin, Wang Qianfei, Zhou Jianfeng, Xiao Zhijian, Bridges James P, Marsh Rebecca A, Zhang Kejian, Jordan Michael B, Li Yuhua, Huang Gang
Abstract excerpt
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by overwhelming immune activation. A steroid and chemotherapy-based regimen remains as the first-line of therapy but it has substantial morbidity. Thus, novel, less toxic therapy for HLH is urgently needed. Although differences exist between familial HLH (FHL) and secondary HLH (sHLH), they have many common features. Using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.